The 20 Best Osteosarcoma Doctors Near Me in District of Columbia, US

Jeffrey Toretsky is a Hematologist and an Oncologist practicing medicine in Washington, Washington, D.c.. Dr. Toretsky is rated as an Elite provider by MediFind in the treatment of Osteosarcoma. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, and Bone Marrow Aspiration.

Matthew Ladra, M.D., M.P.H., leads the dedicated pediatric team for the Johns Hopkins Proton Therapy Center and is the director of pediatric radiation oncology for the Johns Hopkins Kimmel Cancer Center, a clinical collaboration with Children’s National Hospital, where Dr. Ladra serves as faculty in the department of pediatric oncology. He is also an assistant professor of radiation oncology and molecular radiation sciences at the Johns Hopkins School of Medicine. Listen Dr. Ladra's Cancer Matters podcast episode to learn more about his work. Previously, Dr. Ladra served as the director of pediatric radiation at the Provision Center for Proton Therapy in Tennessee. He also completed a 2-year fellowship in pediatric proton therapy at the Massachusetts General Hospital’s Francis H. Burr Proton Center. Dr. Ladra is one of a handful of radiation oncologists whose research and clinical efforts focus exclusively on pediatric patients. He is frequently invited to speak on pediatric radiation oncology topics internationally and across the U.S. and has published extensively on the subject through original research book chapters and review articles. Dr. Ladra’s research efforts focus mainly on pediatric rhabdomyosarcoma treatment, early phase clinical trials involving radiation and non-chemotherapeutic agents, and reducing neurocognitive toxicity for pediatric brain tumor patients. LinkedIn https://www.linkedin.com/in/matthew-ladra-3094a316. Dr. Ladra is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Rhabdomyosarcoma, Muscle Invasive Bladder Cancer, Adult Soft Tissue Sarcoma, and Ependymoma. Dr. Ladra is board certified in American Board Of Radiology.

Karim Boudadi, M.D., is a medical oncologist and hematologist with the Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital in Washington, D.C., and an assistant professor in the Department of Oncology at Johns Hopkins University School of Medicine. Listen to Dr. Boudadi’s Cancer Matters podcast episode to learn more about his work. Dr. Boudadi has expertise in treating cancers of the head and neck, including salivary gland cancers, as well as cancers of the esophagus, and bone and soft tissue sarcomas. Having completed dual training in medical oncology and hematology at Johns Hopkins University, Dr. Boudadi also treats patients with benign hematologic conditions or non-cancer related blood disorders, such as anemia, low blood counts, bleeding disorders, and clotting disorders. Dr. Boudadi earned his medical degree from the University of Rochester School of Medicine. He completed a residency in internal medicine at the University of Michigan in Ann Arbor, MI, and went on to serve as a clinical lecturer in the Department of Internal Medicine at the University of Michigan Medical School before joining Johns Hopkins. He then completed dual fellowship training in both hematology and medical oncology at the Johns Hopkins University School of Medicine. Dr. Boudadi's research during his fellowship focused on prostate cancer and immunotherapy. Dr. Boudadi is a member of the American Society of Clinical Oncology, the American Society of Hematology, the American College of Physicians, and the American Medical Association. He is also a member of the Hematology and Oncology Fellowship Selection Committee at The Johns Hopkins University School of Medicine. Dr. Boudadi has extensive clinical trial development experience and has published his work in peer-reviewed journals. His primary research interest is immunotherapy. Recent News Articles and Media Coverage Cancer Matters Podcast: Dr. Bill Nelson discussing the treatment of HPV related head and neck cancers, Johns Hopkins Kimmel Cancer Center Podcasts (May 23, 2019). Dr. Boudadi is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Glioma, Mesenchymoma, Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, and Prostatectomy. Dr. Boudadi is board certified in American Board Of Internal Medicine.

Robert Henshaw, MD, is the director of Orthopaedic Oncology at Children’s National Hospital. Dr. Henshaw is board-certified in orthopaedic surgery specializes in orthopaedic oncology. He is renowned for introducing minimally invasive procedures for children with bone tumors and performing cutting-edge limb sparing surgery for children with sarcomas (cancer of the musculoskeletal system) using a variety of innovative techniques including expandable implants for growing children. He is also a Professor of Orthopaedic Surgery at Georgetown University School of Medicine. Dr. Henshaw is rated as an Advanced provider by MediFind in the treatment of Osteosarcoma. He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Bone Tumor, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma Embryonal, Osteotomy, and Bone Graft. Dr. Henshaw is board certified in Orthopaedic Surgery: American Board Of Orthopaedic Surgery, 1999.

Jeffrey Dome, MD, PhD, is senior vice president of the Cancer and Blood Disorders Center at Children’s National Hospital in Washington, D.C. He is professor of pediatrics at the George Washington University School of Medicine and Health Sciences and the Thomas Willson and Lenore Williams McKnew professor of pediatric oncology. Dr. Dome received his medical degree from the University of Pennsylvania School of Medicine and PhD degree in medicine from Erasmus University in Rotterdam. He completed a residency in pediatrics at Yale-New Haven Hospital and completed a fellowship in pediatric hematology/oncology at Johns Hopkins Hospital. After fellowship, Dr. Dome was a faculty member at St. Jude Children’s Research Hospital before joining Children’s National in 2006. Dr. Dome is an internationally recognized expert on pediatric solid tumors, with an emphasis on kidney tumors and sarcomas. He chaired the Children’s Oncology Group (COG) Renal Tumor Committee for more than a decade. He is presently on the Scientific Council of the COG, the editorial board of Pediatric Blood and Cancer, and is past chair of the American Board of Pediatrics Subboard of Hematology/Oncology. Dr. Dome serves on numerous medical advisory boards for cancer foundations and currently is the North American Continental President of the International Society of Pediatric Oncology (SIOP). He has authored more than 200 articles, books, letters and chapters on pediatric cancer. Dr. Dome is rated as an Advanced provider by MediFind in the treatment of Osteosarcoma. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Rhabdoid Tumor, Denys-Drash Syndrome (DDS), Adult Soft Tissue Sarcoma, Nephrectomy, and Bone Marrow Aspiration. Dr. Dome is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 1998.

Dennis Priebat is a Hematologist practicing medicine in Washington, Washington, D.c.. Dr. Priebat is rated as an Advanced provider by MediFind in the treatment of Osteosarcoma. He is also highly rated in 29 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Rhabdomyosarcoma Embryonal.

Holly Meany, MD, is a pediatric oncologist and director of the Solid Tumor Program at Children’s National Hospital. She also serves as an associate professor of pediatrics at George Washington University. Dr. Meany is dedicated to finding better treatments for children with cancer through research and clinical care. Her work focuses on developing new therapies for pediatric solid tumors. She designs and leads early-phase clinical trials to test promising treatments and understand how they work in children. Dr. Meany has played a key role in several national studies, including large trials for neuroblastoma, a type of childhood cancer. She recently led an international study for children with newly diagnosed non-high-risk neuroblastoma and is currently helping to develop the next high-risk neuroblastoma trial, both through the Children’s Oncology Group. Dr. Meany is also exploring innovative approaches like immunotherapy—using the body’s own immune system to fight cancer. She has led international studies using specialized T cells to treat patients with relapsed solid tumors and is now working on combining these novel T cells with CAR T-cell therapy for children with relapsed cancers. In addition to her research, Dr. Meany is passionate about training the next generation of pediatric cancer specialists. As director of the Pediatric Hematology-Oncology Fellowship Program at Children’s National, she mentors and supports future leaders in the field. Dr. Meany is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Neuroblastoma, Hereditary Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Osteosarcoma, and Mastoidectomy. Dr. Meany is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2006 and Pediatrics: American Board Of Pediatrics, 2003.

"Eugene (Gene) Hwang, MD, is chief of the Division of Oncology at Children’s National Hospital in Washington, D.C. He is also part of the Children's National Hospital pediatric neuro-oncology team, focusing on treating children with brain tumors. Dr. Hwang has developed and led many novel early phase therapeutic clinical trials with a focus on immunotherapeutic trials, and he also leads trials focused on gene therapy and new, targeted agents. He is the site Principal Investigator of the Pediatric Brain Tumor Consortium, where he is the co-chair of the Immunotherapy Working Group. He serves on grant review committees and on the scientific advisory boards of several large foundations. For each patient, Dr. Hwang carefully considers the best possible options for treatment, trying new, cutting edge treatments coupled with the best available known therapies. Dr. Hwang is not only dedicated to finding a cure for cancer, but also to making the current treatments as safe as possible for children: ""We often focus on curing the children - that's the number one goal - but we also need to pay attention to the toxicity of these treatments, and what quality of life the children will have after treatment."" Dr. Hwang is involved in several international efforts to study how to best mitigate treatment side effects. In the meantime, Dr. Hwang makes sure he is doing everything he can to combat pain, dizziness, fatigue and other common side effects of cancer treatments by leveraging the multidisciplinary team approach of Children's National. He sees this as something the organization does exceptionally well, and thinks that having so many people focus on a single patient in a single visit is crucial to well-being during cancer treatment.". Dr. Hwang is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Pineocytoma, Glioma, Medulloblastoma, and Pineoblastoma. Dr. Hwang is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2009 and Pediatrics: American Board Of Pediatrics, 2005.

Reuven Schore, MD, is a pediatric oncologist and a member of the Leukemia/Lymphoma Program at Children's National Hospital. Dr. Schore is an associate professor, pediatrics at George Washington University School of Medicine. Dr. Schore is the vice chair for a Children's Oncology Group study investigating intravenous treatments for patients with high-risk acute lymphoblastic leukemia (ALL). Dr. Schore is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Juvenile Myelomonocytic Leukemia (JMML), and Febrile Neutropenia. Dr. Schore is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2006 and Pediatrics: American Board Of Pediatrics, 2003.

Nita L. Seibel, MD, is a board-certified pediatrician and pediatric hematologist-oncologist. After graduating from the Ohio State University College of Medicine in 1988, she completed her internship and residency at the Ohio State University Children’s Hospital in 1984. Dr. Seibel completed a fellowship in pediatric hematology-oncology at the Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health in 1987. She joined the faculty of Children's National Hospital in 1988 and is a professor of pediatrics at the George Washington University School of Medicine & Health Sciences. While at Children's National, Dr. Seibel has served for over 15 years on the Institutional Review Board, as Director of the Hematology/Oncology Training Program for nine years and as Principal Investigator for Children's Oncology Group. Dr. Seibel has chaired numerous studies for the Children’s Oncology Group including chairing the Phase I Data Safety Monitoring Committee and served as vice-chair for Phase I agents. Dr. Seibel was also a member of the National Wilms Tumor Study and later the COG Renal Tumor Committee. Dr. Seibel's areas of special interest are: Wilms tumor, bone tumors, ALL, and adolescent and young adult oncology as well as late effects. She also has a special interest in Acute Lymphoblastic Leukemia in adolescents and young adults and anti-fungal agents. Dr. Seibel is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. She is also highly rated in 1 other condition, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult Soft Tissue Sarcoma, and Infantile Neutropenia. Dr. Seibel is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 1987 and Pediatrics: American Board Of Pediatrics, 1986.

Hannah Kinoshita, MD, is an oncologist in the Division of Oncology in the Center for Cancer and Blood Disorders. Her research interests include cellular immunotherapy for high-risk hematologic malignancies. Dr. Kinoshita is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. Her clinical expertise encompasses Multisystem Inflammatory Syndrome in Children (MIS-C), Acute Lymphoblastic Leukemia (ALL), Leukemia, Medulloblastoma, and Bone Marrow Transplant. Dr. Kinoshita is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2023 and American Board Of Pediatrics, 2018.

Dr. Andrea D. Hulse-Johnson is an internist at Sibley Memorial Hospital. She provides outpatient primary care to adults for prevention guidance and chronic disease management. Dr. Hulse-Johnson is a Sibley Primary Care physician who practices out of Sibley Memorial Hospital’s Medical Building, suite 300. Dr. Hulse-Johnson earned her medical degree from A.T. Still University Kirksville College of Osteopathic Medicine. She completed a family practice residency at West Jersey Hospital – Virtua Health. Dr. Hulse is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. Her clinical expertise encompasses Familial Hypertension, Hypertension, Glucocorticoid-Remediable Aldosteronism, and Enlarged Liver. Dr. Hulse is board certified in American Board Of Family Medicine.

Luca Szalontay is a Pediatric Hematologist Oncology provider practicing medicine in Washington, Washington, D.c.. She has been practicing medicine for over 17 years. Dr. Szalontay is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses Glioma, Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, and Brain Stem Cancer. Dr. Szalontay is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2021 and Pediatrics: American Board Of Pediatrics, 2015.

Lindsay Kilburn, MD, comes to Children's National Hospital from Texas Children’s Hospital in Houston, TX, where she was an assistant professor of pediatrics in the neuro-oncology and pharmacology programs. Dr. Kilburn graduated with a degree in Environmental Sciences from the University of Virginia. After graduating from Eastern Virginia Medical School, she completed her pediatric training at the Children’s Hospital of The King’s Daughters in Norfolk, VA, and her hematology/oncology fellowship at Texas Children’s Hospital/Baylor College of Medicine in Houston, TX. She also has received training in pharmacology from both Thomas Jefferson University in Philadelphia and the Baylor College of Medicine in Houston. Dr. Kilburn is an associate professor, pediatrics at George Washington University School of Medicine. Her research focuses on the development and evaluation of new therapeutic agents for children with pediatric brain tumors through clinical trials. She is committed to the improvement of palliative and supportive care. Dr. Kilburn grew up outside of Philadelphia and is married with young twins. Outside of work, she enjoys sailing, hiking, and traveling with her family. Dr. Kilburn is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Glioma, and Optic Glioma. Dr. Kilburn is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2009 and Pediatrics: American Board Of Pediatrics, 2004.

Brian R. Rood, MD, is the director of clinical neuro-oncology and the medical director of the Brain Tumor Institute at Children's National Hospital. Dr. Rood is also a principal investigator in the Center for Cancer and Immunology Research at Children's National Research Institute and a professor of pediatrics at the George Washington University School of Medicine and Health Sciences and adjunct professor at the Fralin Biomedical Research Institute at Virginia Tech. He received a Bachelor of Arts in English Literature from The Pennsylvania State University and completed medical school at Jefferson Medical College. He completed his pediatric residency training at the University of Vermont. Dr. Rood received his pediatric hematology/oncology training at Children's National. He joined the faculty of Children’s National in 2002 after completing a fellowship in pediatric hematology/oncology, as well as a research fellowship in the molecular biology of brain tumors, both at Children’s National and Children’s National Research Institute. Currently, Dr. Rood’s research focuses on the application of proteomics in cancer biology investigation, neoantigen identification and biomarker development. He has also been studying the contribution of germline microsatellite genotypes to pediatric brain tumor predisposition. He currently serves as the executive co-chair of the Children’s Brain Tumor Network, an international consortium of 28 institutions that maintains the world’s largest pediatric brain tumor tissue and data repository, which are freely provided to the research community to support the development of groundbreaking clinical trials through data-driven precision medicine. Dr. Rood has two children. His favorite pastimes include designing and building furniture, sailing, reading, and playing the mandolin. Dr. Rood is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, and Diffuse Midline Glioma H3 K27M-Mutant. Dr. Rood is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2002 and Pediatrics: American Board Of Pediatrics, 1998.

Susan Whiteway is a Pediatric Hematologist Oncology provider practicing medicine in Washington, Washington, D.c.. She has been practicing medicine for over 20 years. Dr. Whiteway is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. Her clinical expertise encompasses Chromosome 7p Deletion, Ewing Sarcoma, RASopathies, and Osteosarcoma. Dr. Whiteway is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2013 and Pediatrics: American Board Of Pediatrics, 2009.

Linda Yau is a primary care provider, practicing in Internal Medicine in Washington, Washington, D.c.. Dr. Yau is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. She is also highly rated in 1 other condition, according to our data. Her clinical expertise encompasses Mesenteric Venous Thrombosis, Diabetic Macular Edema (DME), Primary Localized Cutaneous Amyloidosis, and Cardiac Amyloidosis.

Amy Hont is a Hematologist and an Oncologist practicing medicine in Washington, Washington, D.c.. Dr. Hont is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Osteosarcoma, Ewing Sarcoma, and Rhabdoid Tumor.

Ashley Munchel is a Hematologist and an Oncologist practicing medicine in Washington, Washington, D.c.. Dr. Munchel is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. Her clinical expertise encompasses Acquired Amegakaryocytic Thrombocytopenia, Osteosarcoma, Graft Versus Host Disease (GvHD), Hemolytic Disease of the Newborn, and Bone Marrow Transplant.

Dr Addisu is an Orthopedics provider practicing medicine in Washington, Washington, D.c.. Dr. Addisu is rated as an Experienced provider by MediFind in the treatment of Osteosarcoma. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Klippel-Feil Syndrome, Frontonasal Dysplasia Klippel Feil Syndrome, Fractured Spine, Laminectomy, and Spinal Fusion.